|
Candidemia risk and mortality
| | | |
|
Risk of candidemia
|
0.140
|
0.048 to 0.283
|
See Table S1 in Additional data file 1
|
|
Risk of CK/CG among candidemia
|
0.148
|
0.132 to 0.361
|
See Table S2 in Additional data file 1
|
|
Candidemia attributable mortality
|
0.4
|
0.2 to 0.8
|
Golan and colleagues [22]
|
|
Mortality reduction with appropriate empiric therapy
|
0.48
|
0.35 to 0.65
|
Morrell and colleagues [12] (inverse)
|
|
Evaluation and treatment
| | | |
|
Days of empiric treatment until availability of C&S results
|
3
|
2 to 4
|
Assumption
|
|
Total duration of appropriate treatment (days)
|
10
|
7 to 14
|
Guideline recommendations of 14 days reduced to 10 days to account for mortalities
|
|
Days of antibiotic treatment if switched from MIC to FLU in response to C&S
|
7
|
4 to 10
|
Total duration of appropriate treatment – Days of empiric treatment until availability of C&S results
|
|
Days of antibiotic treatment if switched from FLU to MIC in response to C&S
|
10
|
7 to 14
|
Total duration of appropriate treatment
|
|
Cost of antibiotics
| | | |
|
MIC ($/100 mg daily IV)
|
$100
|
$80 to 120
|
WHC Pharmacy
|
|
FLU ($/400 mg daily IV)
|
$12
|
$10 to 14
|
WHC Pharmacy
|
|
FLU ($/400 mg single loading dose on day 1)
|
$12
|
$10 to 14
|
WHC Pharmacy
|
|
Life expectancy, QALY adjustment and lifetime costs
| | | |
|
Median age (years)
|
64
|
48 to 80
|
Median from Table S1 in Additional data file 1; range is +/- 25% median
|
|
Life expectancy (years)
|
17.4
|
13.0 to 21.4
|
Actuarial tables from the US Social Security Administration [24]; for men; range is +/-25%
|
|
Relative risk of death
|
0.51
|
0.49 to 0.59
|
Quartin and colleagues [25]
|
|
QALY adjustment
|
0.64
|
0.44 to 0.80
|
Fowler and colleagues [26], and Davies and colleagues [27]
|
|
Age-specific annual healthcare costs/survivor in 2001 $US*
|
$16,446
|
$12,335 to $20,558
|
Shorr and colleagues [29]
|
|
Annual discount rate
|
3%
|
0 to 6%
|
Weinstein and colleagues [19]
|
